



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 3937

**Title:** HER2 therapies and gastric cancer: a step forward

**Reviewer code:** 00058121

**Science editor:** Zhai, Huan-Huan

**Date sent for review:** 2013-06-03 19:30

**Date reviewed:** 2013-06-09 23:57

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

Authors have perfectly gone through the current knowledge considering HER2 therapies and gastric cancer. A brief report not just a list of names of other targeted agents might be on readers' interest e.g: In gastric cancer patients, amplification and expression of c-Met often indicates poor prognosis. Several types of targeted agents have been developed for c-Met pathway. I would expect authors to give some future perspectives: The article does not introduce any idea that appears promising or might stimulate others to develop promising alternatives.



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 3937

**Title:** HER2 therapies and gastric cancer: a step forward

**Reviewer code:** 00504611

**Science editor:** Zhai, Huan-Huan

**Date sent for review:** 2013-06-03 19:30

**Date reviewed:** 2013-06-24 22:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> [ Y] Accept
<input type="checkbox"/> [ Y] Grade B (Very good)	<input type="checkbox"/> [ Y] Grade B: minor language polishing	<input type="checkbox"/> [ ] Existed	<input type="checkbox"/> [ ] High priority for publication
<input type="checkbox"/> [ ] Grade C (Good)	<input type="checkbox"/> [ ] Grade C: a great deal of language polishing	<input type="checkbox"/> [ ] No records	<input type="checkbox"/> [ ] Rejection
<input type="checkbox"/> [ ] Grade D (Fair)	<input type="checkbox"/> [ ] Grade D: rejected	BPG Search:	<input type="checkbox"/> [ ] Minor revision
<input type="checkbox"/> [ ] Grade E (Poor)		<input type="checkbox"/> [ ] Existed	<input type="checkbox"/> [ ] Major revision
		<input type="checkbox"/> [ ] No records	

### COMMENTS TO AUTHORS

This is an interesting review which describes the state-of-the-art of HER2 therapy in gastric cancer. I have suggested minor changes to the text